DNAJB6, DNAJB2, HSPA8, HSPA1A · protein biochemistry · -
Composite 0.620
Price $0.62
Evidence For 0
Evidence Against 0
DNAJB6 (HSP40 family) exhibits selective anti-amyloid activity distinct from DNAJB2, which favors protein refolding. Differential interaction kinetics between specific J-proteins and HSP70 create a 'client code' that preferentially engages with structured β-sheet-rich cores of pathological aggregates versus helical, solvent-exposed intermediates in normal folding trajectories.
HSPA8, HSPA1A, DNAJB6, DNAJB2 · protein biochemistry · -
Composite 0.740
Price $0.74
Evidence For 0
Evidence Against 0
Pathological conformers expose 'aggregation nucleation' sequences—typically 5-15 residue hydrophobic stretches with high β-sheet propensity—that are buried in native folds but become accessible during misfolding. This recognition is mediated by HSP70 isoforms including HSPA8, HSPA1A, and their J-domain co-chaperones DNAJB6 and DNAJB2. Consistent with binding studies demonstrating that HSP70 preferentially binds α-synuclein at the N-terminal and NAC amyloidogenic regions (PMID 29463785), and that
# Critical Evaluation of Chaperone Selectivity Hypotheses
## Hypothesis 1: Co-chaperone Heterogeneity (DNAJB6/DNAJB2)
**Weak Links:**
- The "client code" is descriptive terminology lacking mechanist...
Domain Expert
# Feasibility Assessment: Chaperone Selectivity Hypotheses
## Executive Summary
Of the five hypotheses, **Hypothesis 3 (amyloidogenic segment recognition)** emerges as most feasible for therapeutic ...
# Critical Evaluation of Chaperone Selectivity Hypotheses
## Hypothesis 1: Co-chaperone Heterogeneity (DNAJB6/DNAJB2)
**Weak Links:**
- The "client code" is descriptive terminology lacking mechanist...
Domain Expert
# Feasibility Assessment: Chaperone Selectivity Hypotheses
## Executive Summary
Of the five hypotheses, **Hypothesis 3 (amyloidogenic segment recognition)** emerges as most feasible for therapeutic ...